Postdoctoral Training Fellow - Gene Function
Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.
The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.
OBJECTIVES OF POST
The Gene Function Laboratory, headed by Professor Chris Lord, focuses upon identifying and understanding tumour specific dependencies, such as synthetic lethal effects, as a means to design novel approaches to treating cancer. We have made major advances in identifying synthetic lethal interactions involving, for example, PARP inhibitors (Farmer et al Nature (2005), Edwards et al Nature (2008), Bajrami et al, Cancer Research (2014)), ATR inhibitors (Williamson et al, Nature Communications (2016)) and ROS1 inhibitors (Bajrami et al, Cancer Discovery (2018)). Using this same concept we have also systematically identified synthetic lethal interactions in breast cancer (Brough et al, Cancer Discovery (2011), Campbell et al, Cell Reports (2016)). We also use genetic approaches to understand the mechanisms of action of agents that target the DNA damage response (Pettitt et al; Krastev et al Nature Communications (2018)) We aim to generate pre-clinical information that can inform the design of clinical trials and the identification of novel targets for drug discovery programmes.
We are seeking highly motivated Postdoctoral Training Fellow to study synthetic lethal effects, with the aim of developing optimised treatment approaches for breast cancers with loss of the E-cadherin tumour suppressor, building on our recent work in this area which identified vulnerabilities to the ROS1 inhibitors in these cancers (Bajrami et al, Cancer Discovery (2018)). The successful applicant will extend this work to find potential combination therapies with clinical ROS1 inhibitors such as crizotinib and carry out further research into potential crizotinib resistance mechanisms to inform an ongoing clinical trial based on this research.
The successful applicants will use a combination of high-throughput in vitro and in vivo functional genomic approaches. These may include the use of RNA interference, CRISPR-Cas9 and drug screens. We would expect successful candidates to contribute to the development of a project and research plan that makes the most of the resources and interests of the laboratory as well as the candidate’s specific skill set and experience.
Candidates should possess a PhD in biology, genetics or other associated subjects, experience in molecular and cellular biology and a strong track record of high quality biomedical research as exemplified by their publication record. Successful applicants will enjoy working in an interdisciplinary environment with our internal and external biology, clinical, pathology and computational biology collaborators. The post holders will be fast learners, and will be motivated to explore new subjects.
The salary scale is in the range of £31,023 p.a. to £36,798 p.a. inclusive. Starting salary will be based on previous postdoctoral experience.
Interviews are expected to take place in May/June 2019.
Informal enquiries are welcome and can be made via email to Dr Stephen Pettitt (email@example.com). Please note - this address is for enquiries only and you should not send your application to this email address.
This Program is closed to applications.